AsymBio, a strategic business of Asymchem Group (stock codes: 002821.SZ / 6821.HK), focuses exclusively on one-stop biopharmaceutical CDMO services. Leveraging advanced technology platforms and extensive project experience, AsymBio provides global clients with one-stop CDMO solutions for ADCs and novel bioconjugates, antibodies, and recombinant protein therapeutics. Its capabilities span early-stage research, process development, toxicology batches, clinical batches, and commercial-scale manufacturing, providing fully integrated, end-to-end support across the development lifecycle.

Building on this foundation, AsymBio further integrates Asymchem Group’s resources by connecting its early-stage development and CMC capabilities with Yugen Medtech’s nonclinical evaluation services, Asymchem Clinical (Clin-nov)’s early clinical translation services, and the Group’s digital platform capabilities. Together, these capabilities form the AccPCC (Accelerated PCC Platform), an integrated R&D acceleration platform that establishes a connected workflow from candidate molecule preparation to preclinical candidate (PCC) selection and seamlessly transitions into CMC development. This integrated model helps innovative drug programs advance more efficiently into clinical development and toward commercialization.

AsymBio is committed to becoming a trusted partner for biopharmaceutical companies worldwide, empowering global biopharmaceutical innovation and accelerating the path to market.